Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization

Table 1 Expression of lipoma HMGIC fusion partner-like 2 in transarterial chemoembolization-resistant and non-resistant groups (n = 60), n (%)

Group	Low LHFPL2	High LHFPL2	χ2	P value
TACE-resistant	8 (26.67)	22 (73.33)	17.140	< 0.001
Non-resistant	24 (80.00)	6 (20.00)	-	-

HFPL2: Lipoma HMGIC fusion partner-like 2; TACE: Transarterial chemoembolization.

Table 2 Comparison of clinical and pathological features between transarterial chemoembolization-resistant and non-resistant groups, n (%)

Variable	TACE-resistant (n = 30)	Non-resistant (n = 30)	χ2/t/Z	P value
Sex			1.200	0.273
Male	18 (60.00)	22 (73.33)
Female	12 (40.00)	8 (26.67)
Age (years), mean ± SD	64.40 ± 10.53	64.27 ± 10.61	0.048	0.962
HBV carrier			6.787	0.010
Yes	22 (73.33)	12 (40.00)
No	8 (26.67)	18 (60.00)
Cirrhosis			3.360	0.067
Yes	16 (53.33)	9 (30.00)
No	14 (46.67)	21 (70.00)
AFP level			-	< 0.001
≥ 400 ng/mL	18 (60.00)	4 (13.33)
< 400 ng/mL	12 (40.00)	26 (86.67)
Tumor size			2.443	0.118
> 3 cm	20 (66.67)	14 (46.67)
≤ 3 cm	10 (33.33)	16 (53.33)
Histologic differentiation			8.131	0.017
Poor	15 (50.00)	5 (16.67)
Moderate	7 (23.33)	15 (50.00)
Well	8 (26.67)	10 (33.33)

TACE: Transarterial chemoembolization; HBV: Hepatitis B virus; AFP: Alpha-fetoprotein.

Table 3 Univariate and multivariate Cox analyses of prognostic survival in patients with hepatocellular carcinoma

Index	Univariate analysis			Multiple factor
	HR	95%CI	P value	HR	95%CI	P value
Age	1.040	1.000-1.084	0.067	-	-	-
Sex	0.688	0.318-2.920	0.342	-	-	-
HBV carrier	1.931	0.877-4.253	0.102	-	-	-
Cirrhosis	1.977	0.925-4.226	0.079	-	-	-
AFP ≥ 400 ng/mL	13.483	4.634-39.226	< 0.001	38.632	5.274-282.970	< 0.001
Tumor size > 3 cm	1.695	0.758-3.787	0.198	-	-	-
Poor differentiation	0.584	0.341-1.001	0.050	-	-	-
High LHFPL2	4.490	1.950-10.341	< 0.001	5.408	1.569-18.642	0.008
TACE refractoriness	12.444	4.131-37.489	< 0.001	6.955	1.458-33.170	0.015

CI: Confidence interval; HR: Hazard ratio; HBV: Hepatitis B virus; AFP: Alpha-fetoprotein; HFPL2: Lipoma HMGIC fusion partner-like 2; TACE: Transarterial chemoembolization.